Publications by authors named "Changan Chu"
Article Synopsis
- The DESTINY-Breast02 trial aimed to evaluate the effectiveness and safety of trastuzumab deruxtecan compared to physician's choice treatments in patients with HER2-positive metastatic breast cancer who had previously been treated with trastuzumab emtansine.
- Conducted at 227 sites across multiple countries, this phase 3 trial involved randomly assigning 608 eligible patients to either trastuzumab deruxtecan or a choice of other drugs, with the primary goal of assessing progression-free survival.
- Findings showed that 608 patients were analyzed, with a median age of 54.2 years, highlighting the trial's significance for a population lacking treatment options.
The aim of this non-interventional, multi-database, analytical cohort study was to assess the cardiovascular (CV) safety of vildagliptin vs other non-insulin antidiabetic drugs (NIADs) using real-world data from 5 European electronic healthcare databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for the outcomes of interest (myocardial infarction [MI], acute coronary syndrome [ACS], stroke, congestive heart failure [CHF], individually and as a composite) were estimated using negative binomial regression.
View Article and Find Full Text PDF